Is Tarsus Pharmaceuticals, Inc. (TARS) a Buy, Sell, or Hold?
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$56.11 USD
-$3.2 (-5.4%)
- Volume
- 2.08M
- Average Volume
- 881.37K
- Market Capitalization
- $2.41B
- P/E Ratio
- -49.22
- Dividend Yield
- 0.00%
- Price Target
- $68.00
- Year High
- $85.25
- Year Low
- $38.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.74
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Bobak R. Azamian |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TARS |
| CUSIP | 87650L103 |
| CIK | 0001819790 |
| Web | https://www.tarsusrx.com |
| Phone | 949 409 9820 |
| Currency | USD |
| Employees | 370 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.25 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.74 |
| Quick Ratio | 3.71 |
| Cash Ratio | 0.71 |
Sales & Book Value
| Annual Sales | $451.36M |
| Price / Sales | 4.51 |
| Cash Flow | -0.73 |
| Price / Cash Flow | -76.54 |
| Price / Book | 6.91 |
Price Target and Rating
| Average Stock Price Forecast | $68.00 |
| High Stock Price Forecast | $68.00 |
| Low Stock Price Forecast | $68.00 |
| Forecast Upside/Downside | -17.49% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.59 |
| Trailing P/E Ratio | -49.22 |
| PEG Ratio | -0.48 |
| P/E Growth | -0.48 |
| Net Income | $-66.42M |
| Net Margin | -9.02% |
| Pretax Margin | -9.07% |
| Return on Equity | -14.19% |
| Return on Assets | -8.31% |
Financials Score
| AltmanZ Score | 6.69 |
| Piotroski Score | 3.00 |
| Working Capital | 393.72M |
| Total Assets | 581.14M |
| Ebit | -41.98M |
| Market Cap | 2.41B |
| Total Liabilities | 232.18M |
Poll Results
About Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company mai ... ntains its headquarters in Irvine, California.
2026-07-13 16:05:00
IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor.
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
2026-07-11 10:02:19
Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market.
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
2026-07-09 13:01:16
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline.
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
2026-07-09 02:12:27
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
2026-07-08 16:05:00
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
2026-07-08 13:01:12
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
2026-07-03 06:06:03
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tarsus to Participate in Upcoming Investor Conferences
2026-05-28 16:30:00
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Frequently Asked Questions
-
What is the current Tarsus Pharmaceuticals, Inc. (TARS) stock price?
-
Tarsus Pharmaceuticals, Inc.(NASDAQ:TARS) stock price is $56.11 in the last trading session. During the trading session, TARS stock reached the peak price of $85.25 while $38.51 was the lowest point it dropped to. The percentage change in TARS stock occurred in the recent session was --5.4% while the dollar amount for the price change in TARS stock was -$-3.2.
-
TARS's industry and sector of operation?
-
The NASDAQ listed TARS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TARS?
-
Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman
Scott Youmans | Vice President of Sales
Adrienne Kemp | Senior Director of Corporate Communications
Cara Miller | Senior Vice President of Corporate Affairs
Dianne C. Whitfield | Chief Human Resources Officer -
How many employees does TARS have?
-
Number of TARS employees currently stands at 370. TARS operates from 15440 Laguna Canyon Road, Irvine, CA 92618, US.
-
Link for TARS official website?
-
Official Website of TARS is: https://www.tarsusrx.com
-
How do I contact TARS?
-
TARS could be contacted at phone #949 409 9820 and can also be accessed through its website. TARS operates from 15440 Laguna Canyon Road, Irvine, CA 92618, US.
-
How many shares of TARS are traded daily?
-
The average number of TARS shares traded daily for last 3 months was 881.37K.
-
What is the market cap of TARS currently?
-
The market value of TARS currently stands at $2.41B with its latest stock price at $56.11